References
- 1. Adamson CS, Chibale K, Goss RJM, Jaspars M, Newman DJ, Dorrington RA (2021) Antiviral drug discovery: preparing for the next pandemic. Chem Soc Rev 50:3647–3655. doi: 10.1039/D0CS01118E10.1039/D0CS01118E33524090
- 2. Agrawal U, Raju R, Udwadia ZF (2020) Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 76:370–376. doi: 10.1016/j.mjafi.2020.08.00410.1016/j.mjafi.2020.08.004746706732895599
- 3. Akilesh SM, J R, Palanisamy D, Wadhwani A (2021) Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight. Curr Pharm Biotechnol 22:192–199. doi:10.2174/138920102199920082015592710.2174/138920102199920082015592732867651
- 4. Amendola G, Ettari R, Previti S, Di Chio C, Messere A, Di Maro S, Hammerschmidt SJ, Zimmer C, Zimmermann RA, Schirmeister T, Zappalà M, Cosconati S (2021) Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening. J Chem Inf Model 61:2062–2073. doi: 10.1021/acs.jcim.1c0018410.1021/acs.jcim.1c00184802944733784094
- 5. Antiviral Therapy [WWW Document] (Last updated: 11 Feb 2021) COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ Accessed 20 May 2021
- 6. Azam F, Taban IM, Eid EEM, Iqbal M, Alam O, Khan S, Mahmood D, Anwar MJ, Khalilullah H, Khan MU (2020) An insilico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α. J Biomol Struct Dyn 1–14. doi: 10.1080/07391102.2020.184102810.1080/07391102.2020.1841028764342233131430
- 7. Bello M (2021) Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets. J Biomol Struct Dyn 1–9. doi: 10.1080/07391102.2021.191185710.1080/07391102.2021.1911857805493633843474
- 8. Benlloch J-M, Cortés J-C, Martínez-Rodríguez D, Julián R-S, Villanueva R-J (2020) Effect of the early use of antivirals on the COVID-19 pandemic. A computational network modeling approach. Chaos Soliton Fract 140:110168. doi: 10.1016/j.chaos.2020.11016810.1016/j.chaos.2020.110168743436832836917
- 9. Bhowmick S, Dang A, Vallish BN, Dang S (2021) Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review. Drug Saf. doi: 10.1007/s40264-021-01066-y10.1007/s40264-021-01066-y805154833864232
- 10. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res 178:104787. doi: 10.1016/j.antiviral.2020.10478710.1016/j.antiviral.2020.104787712905932251768
- 11. Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, Chen Y, Wu JJ (2020) First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. Medicine (Baltimore) 99. doi: 10.1097/MD.000000000002335710.1097/MD.0000000000023357771019233235105
- 12. Choudhury A, Das NC, Patra R, Bhattacharya M, Ghosh P, Patra BC, Mukherjee S (2021) Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach. Future Virol 16:277–291. doi: 10.2217/fvl-2020-034210.2217/fvl-2020-0342
- 13. Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FFS, Sherief AF, Elgaafary M, Fawzy E, Hassany SM, Riad AR, TagelDin MA (2021) Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci Rep-UK 11:7282. doi: 10.1038/s41598-021-85227-010.1038/s41598-021-85227-0
- 14. Dolgin E (2021) The race for antiviral drugs to beat COVID — and the next pandemic. Nature 592:340–343. doi: 10.1038/d41586-021-00958-410.1038/d41586-021-00958-4
- 15. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD (2020) Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci 6:672–683. doi: 10.1021/acscentsci.0c0048910.1021/acscentsci.0c00489
- 16. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, Cuscó MD-A, Ferrández O, Horcajada JP, Grau S (2021) Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti-infe 19:147–163. doi: 10.1080/14787210.2020.181302410.1080/14787210.2020.1813024
- 17. Everts M, n.d. Antiviral Drug Discovery and Development Center | UAB [WWW Document]. https://www.uab.edu/medicine/ad3c/ Accessed 20 May 2021
- 18. FDA (2020) Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment [WWW Document]. FDA. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment Accessed 30 Sep 2020
- 19. FDA (2021) COVID-19 Vaccines. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines Accessed 21 May 2021
- 20. Frediansyah A, Tiwari R, Sharun K, Dhama K, Harapan H (2021) Antivirals for COVID-19: A critical review. Clin Epidemiol Glob Health 9:90–98. doi: 10.1016/j.cegh.2020.07.00610.1016/j.cegh.2020.07.006
- 21. Gatti M, De Ponti F (2021) Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics 13. doi: 10.3390/pharmaceutics1303030210.3390/pharmaceutics13030302
- 22. Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M (2021) Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. doi: 10.1016/j.jbc.2021.10077010.1016/j.jbc.2021.100770
- 23. Glaus MJ, Von Ruden S (2020) Remdesivir and COVID-19. The Lancet 396:952. doi: 10.1016/S0140-6736(20)32021-310.1016/S0140-6736(20)32021-3
- 24. Halford B (2021) PROCESS CHEMISTRY Chemists shorten synthesis of molnupiravir. Chem. Eng. News 99, 7–7.
- 25. Hospital do Coracao (2020) Antiviral for Adult Patients Hospitalized for SARSCoV-2 Infection: a Randomized, Phase 2/3, Multicenter, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX: REVOLUTIOn (Clinical trial registration No. NCT04468087). clinicaltrials.gov.
- 26. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, Ng Y-Y, Lo J, Chan J, Tam AR, Shum H-P, Chan V, Wu AK-L, Sin K-M, Leung W-S, Law W-L, Lung DC, Sin S, Yeung P, Yip CC-Y, Zhang RR, Fung AY-F, Yan EY-W, Leung K-H, Ip JD, Chu AW-H, Chan W-M, Ng AC-K, Lee R, Fung K, Yeung A, Wu T-C, Chan JW-M, Yan W-W, Chan W-M, Chan JF-W, Lie AK-W, Tsang OT-Y, Cheng VC-C, Que T-L, Lau C-S, Chan K-H, To KK-W, Yuen K-Y (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet 395:1695–1704. doi: 10.1016/S0140-6736(20)31042-410.1016/S0140-6736(20)31042-4
- 27. Jomah S, Asdaq SMB, Al-Yamani MJ (2020) Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. J Infect Public Heal 13:1187–1195. doi: 10.1016/j.jiph.2020.07.01310.1016/j.jiph.2020.07.013
- 28. Jourdan J-P, Bureau R, Rochais C, Dallemagne P (2020) Drug repositioning: a brief overview. J Pharm Pharmacol 72:1145–1151. doi: 10.1111/jphp.1327310.1111/jphp.13273
- 29. Kaka AS, MacDonald R, Greer N, Vela K, Duan-Porter W, Obley A, Wilt TJ (2021) Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. doi: 10.7326/M20-814810.7326/M20-8148
- 30. Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B (2021) Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. doi: 10.1007/s43440-020-00195-y10.1007/s43440-020-00195-y
- 31. Kouznetsov VV (2020) COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. Eur J Med Chem 203:112647. doi: 10.1016/j.ejmech.2020.11264710.1016/j.ejmech.2020.112647
- 32. Lai C-C, Chen C-H, Wang C-Y, Chen K-H, Wang Y-H, Hsueh P-R (2021) Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. doi: 10.1093/jac/dkab09310.1093/jac/dkab093
- 33. Lee N, Ison M, Dunning J (2020) Early triple antiviral therapy for COVID-19. The Lancet 396:1487–1488. doi: 10.1016/S0140-6736(20)32274-110.1016/S0140-6736(20)32274-1
- 34. Marcolino VA, Pimentel TC, Barão CE (2020) What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. Eur J Pharmacol 887:173467. doi: 10.1016/j.ejphar.2020.17346710.1016/j.ejphar.2020.173467741441932777212
- 35. Mendieta Zerón H, Meneses Calderón J, Paniagua Coria L, Meneses Figueroa J, Vargas Contreras MJ, Vives Aceves HL, Carranza Salazar FM, Californias Hernández D, Miraflores Vidaurri E, Carrillo González A, Anaya Herrera J (2021) Nitazoxanide as an early treatment to reduce the intensity of COVID-19 outbreaks among health personnel. World Academy of Sciences Journal 3:1–6. doi: 10.3892/wasj.2021.9410.3892/wasj.2021.94
- 36. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR (2021) Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. doi: 10.1128/AAC.02428-2010.1128/AAC.02428-20809291533649113
- 37. Pani A, Lauriola M, Romandini A, Scaglione F (2020) Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Ag 56:106053. doi: 10.1016/j.ijantimicag.2020.10605310.1016/j.ijantimicag.2020.106053728625632534189
- 38. Pérez-Moraga R, Forés-Martos J, Suay-García B, Duval J-L, Falcó A, Climent J (2021) A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. Pharmaceutics 13:488. doi: 10.3390/pharmaceutics1304048810.3390/pharmaceutics13040488806615633918313
- 39. Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2 | pfpfizeruscom [WWW Document] (23 Mar 2021) https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral Accessed 21 May 2021
- 40. Pfizer unveils its oral SARS-CoV-2 inhibitor [WWW Document] (07 Apr 2021) Chemical & Engineering News. https://cen.acs.org/acs-news/acs-meeting-news/Pfizer-unveils-oral-SARSCoV/99/i13 Accessed 21 May 2021
- 41. Pinho AC (2021) COVID-19 vaccines [WWW Document]. European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines Accessed 19 May 2021
- 42. Reina J (2021) [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2]. Rev Esp Quimioter. doi: 10.37201/req/042.202110.37201/req/042.2021863883133902254
- 43. Repurposed Antiviral Drugs for Covid-19— Interim WHO Solidarity Trial Results (2021) New Engl J Med 384:497–511. doi: 10.1056/NEJMoa202318410.1056/NEJMoa2023184772732733264556
- 44. Richman DD (2020) Antiviral Drug Discovery To Address the COVID-19 Pandemic. mBio 11. doi: 10.1128/mBio.02134-2010.1128/mBio.02134-20752060032978312
- 45. Ridgeback Biotherapeutics, LP (2021) The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2 (Clinical trial registration No. NCT04405739). clinicaltrials.gov.
- 46. Robinson J (19 Oct 2020) Antivirals have little effect on mortality in patients hospitalised with COVID-19, suggest WHO trial interim results [WWW Document]. The Pharmaceutical Journal. https://pharmaceutical-journal.com/article/news/antivirals-have-little-effect-on-mortality-in-patients-hospitalised-with-covid-19-suggest-who-trial-interim-results Accessed 30 Apr 2021
- 47. Rocco PRM, Silva PL, Cruz FF, Junior MACM, Tierno PFGMM, Moura MA, Oliveira LFGD, Lima CC, Santos EAD, Junior WF, Fernandes APSM, Franchini KG, Magri E, Moraes NF, de Gonçalves JMJ, Carbonieri MN, Santos ISD, Paes NF, Maciel PVM, Rocha RP, Carvalho AF, de Alves PA, Modena JLP, Cordeiro AT, Trivella DBB, Marques RE, Luiz RR, Pelosi P, Silva JRL (2020) Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J. doi: 10.1183/13993003.03725-202010.1183/13993003.03725-2020775877833361100
- 48. Sahakijpijarn S, Moon C, Koleng JJ, Christensen DJ, Williams RO (2020) Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing. Pharmaceutics 12:1002. doi: 10.3390/pharmaceutics1211100210.3390/pharmaceutics12111002769037733105618
- 49. Sahakijpijarn S, Moon C, Warnken ZN, Maier EY, DeVore JE, Christensen DJ, Koleng JJ, Williams RO (2021) In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters. International Journal of Pharmaceutics: X 3:100073. doi: 10.1016/j.ijpx.2021.10007310.1016/j.ijpx.2021.100073868366434977555
- 50. Salvi SS (2021) Is there a role for inhaled ciclesonide in the treatment of COVID-19? Lung India 38:1–4. doi: 10.4103/lungindia.lungindia_473_2010.4103/lungindia.lungindia_473_20806693933402630
- 51. SCCM | COVID-19 Guidelines [WWW Document] (29 Jan 2021) Society of Critical Care Medicine (SCCM). https://sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19 Accessed 12 May 2021
- 52. Şimşek Yavuz S, Ünal S (2020) Antiviral treatment of COVID-19. Turk J Med Sci 50:611–619. doi: 10.3906/sag-2004-14510.3906/sag-2004-145719597932293834
- 53. Solidarity clinical trial for COVID-19 treatments [WWW Document], n.d. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments Accessed 12 Dec 2020
- 54. Srinivas P, Sacha G, Koval C (2020) Antivirals for COVID-19. Clev Clin J Med. doi: 10.3949/ccjm.87a.ccc03010.3949/ccjm.87a.ccc03032409433
- 55. Taher M, Tik N, Susanti D (2021) Drugs intervention study in COVID-19 management. Drug Metab Pers Ther. doi: 10.1515/dmdi-2020-017310.1515/dmdi-2020-017333818031
- 56. Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19 [WWW Document] (17 Jun 2020) https://www.who.int/publications/m/item/targeted-update-safety-and-efficacy-ofhydroxychloroquine-or-chloroquine-for-treatment-of-covid-19 Accessed 13 Oct 2020
- 57. Teoh SL, Lim YH, Lai NM, Lee SWH (2020) Directly Acting Antivirals for COVID-19: Where Do We Stand? Front Microbiol 11. doi: 10.3389/fmicb.2020.0185710.3389/fmicb.2020.01857741965632849448
- 58. Wang J (2020) Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study. doi: 10.26434/chemrxiv.11875446.v110.26434/chemrxiv.11875446.v1
- 59. Xu J, Shi P-Y, Li H, Zhou J (2020) Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. doi: 10.1021/acsinfecdis.0c0005210.1021/acsinfecdis.0c00052709806932125140
- 60. Zhang Z, Wang S, Tu X, Peng X, Huang Y, Wang L, Ju W, Rao J, Li X, Zhu D, Sun H, Chen H (2020) A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol 92:2631–2636. doi: 10.1002/jmv.2614110.1002/jmv.26141730066732501538